CymaBay Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

CymaBay Therapeutics (NASDAQ: CBAY) announced participation in three virtual investor conferences, enhancing its investor relations outreach. The conferences include the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, the Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020, and the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 3, 2020. The company is focused on developing therapies for liver diseases, particularly seladelpar, which has received multiple designations from the FDA and EMA.

NEWARK, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three virtual investor conferences including Stifel 2020 Virtual Healthcare Conference taking place November 16-19, 2020, the Evercore ISI 3^rd Annual HealthCONx Conference taking place December 1-3, 2020, and the Piper Sandler 32^nd Annual Virtual Healthcare Conference taking place December 1- 3, 2020.

Stifel’s 2020 Virtual Healthcare Conference
Date:	Tuesday, November 17
Time:	1:20 pm Eastern Time
Webcast:	http://ir.cymabay.com/events
Evercore ISI 3rd Annual HealthCONx Conference
Date:	Tuesday, December 1
Time:	3:55 pm Eastern Time / Track 4
Webcast:	http://ir.cymabay.com/events
Piper Sandler 32nd Annual Virtual Healthcare Conference
Date:	Thursday, December 3, 2020
Time:	9:00 am Eastern Time
Webcast:	http://ir.cymabay.com/events

About CymaBay

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay is developing seladelpar, a potent, selective, orally active PPARδ agonist for patients with primary biliary cholangitis (PBC). Seladelpar has received an orphan designation from the US Food and Drug administration (FDA) and the European Medicine Agency (EMA). Seladelpar also received Breakthrough Therapy Designation from the FDA for early stage PBC and PRIority MEdicines status from the EMA.

Cautionary Statements

Any statements made in this press release and at the investor conferences referenced above regarding the potential for seladelpar to treat PBC and potentially improve clinical symptoms of the disease, the potential benefits to patients, its current and future clinical trials and CymaBay’s ability to fund current and planned clinical trials are forward looking statements that are subject to risks and uncertainties. Actual results and the timing of events regarding the further development of seladelpar could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of any of CymaBay's product development activities, including clinical trials; effects observed in trials to date that may not be repeated in the future; any delays or inability to obtain or maintain regulatory approval of CymaBay's product candidates in the United States or worldwide; and the ability of CymaBay to obtain sufficient financing to complete development, regulatory approval and commercialization of its product candidates in the United States and worldwide. Additional risks relating to CymaBay are contained in CymaBay's filings with the Securities and Exchange Commission, including without limitation its most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. CymaBay disclaims any obligation to update these forward-looking statements except as required by law.

For additional information about CymaBay visit www.cymabay.com.

Public Relations Contact:

Glenn Silver
Lazar-FINN Partners
(973) 818-8198
Glenn.silver@finnpartners.com

Investor Relations Contact:

Hans Vitzthum
LifeSci Advisors, LLC
(617) 430-7578
Hans@LifeSciAdvisors.com

FAQ

What are the dates of the investor conferences CymaBay is participating in?

CymaBay is participating in the Stifel conference on November 17, Evercore ISI conference on December 1, and Piper Sandler conference on December 3, 2020.

What is seladelpar and its significance for CymaBay?

Seladelpar is a potent PPARδ agonist being developed by CymaBay for patients with primary biliary cholangitis, having received orphan designation and Breakthrough Therapy Designation from the FDA.

Where can I watch the webcasts of the CymaBay conferences?

The webcasts for the investor conferences can be accessed at ir.cymabay.com/events.

What is the focus of CymaBay Therapeutics?

CymaBay Therapeutics focuses on developing therapies for liver diseases and other chronic conditions with high unmet medical needs.

What should investors know about CymaBay's forward-looking statements?

Investors should be aware that CymaBay's forward-looking statements regarding seladelpar's efficacy and clinical trials are subject to risks and uncertainties that may affect actual results.